Taigen Biopharmaceuticals Holdings Ltd (4157) — Cash Flow Reinvestment Rate
Taigen Biopharmaceuticals Holdings Ltd (4157) has a Cash Flow Reinvestment Rate of 0.84x as of December 2025, reinvesting NT$39.01 Million (capex NT$2.24 Million plus investments NT$36.77 Million) from operating cash flow of NT$46.51 Million. Check Taigen Biopharmaceuticals Holdings Ltd earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Taigen Biopharmaceuticals Holdings Ltd Cash Flow Reinvestment Rate (2021–2025)
Historical reinvestment intensity for Taigen Biopharmaceuticals Holdings Ltd across 3 annual periods. Explore Taigen Biopharmaceuticals Holdings Ltd (4157) investment intensity to see how much of total assets are deployed in long-term investments.
Annual Cash Flow Reinvestment Rate for Taigen Biopharmaceuticals Holdings Ltd (2021–2025)
Year-by-year capital reinvestment analysis for Taigen Biopharmaceuticals Holdings Ltd. For live market cap and broader valuation context, see 4157 company net worth.
| Year | Reinvestment Rate | Total Reinvested (TWD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 2.99x | NT$62.64 Million | NT$20.93 Million | NT$4.50 Million | ▼ -59.4% |
| 2023 | 7.37x | NT$152.85 Million | NT$20.74 Million | NT$7.39 Million | ▲ +1396.0% |
| 2021 | 0.49x | NT$309.90 Million | NT$629.07 Million | NT$11.83 Million | — |